AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03180398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Description: MRI will be acquired before, during and after radiation treatment to evaluate treatment response
Study NCT01863134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Study NCT01863134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00385723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 (Fish Oil) Supplementation
Description: 1.25 g or 2.496 g daily for 4 months
Study NCT00385723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule daily for 4 months
Study NCT01555554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol.
Study NCT01555554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo.
Study NCT02914548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Description: Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
Study NCT02914548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
Study NCT01711359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Administered orally every day
Study NCT01886092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 1
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
Study NCT01886092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 2
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
Study NCT03420651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peak Expiratory Flow Rate (PEFR)
Description: PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
Study NCT03420651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Clinical Judgement
Description: Providers will use physical exam and standard clinical judgement to guide management.
Study NCT01184625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: 12 weeks of physical exercise.
Study NCT03176992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL®
Description: insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
Study NCT00483808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ardian Symplicity™ Catheter
Description: Renal denervation using the Symplicity Catheter
Study NCT04290689 — intervention group
Intervention type: DRUG
Intervention: Botulinum Toxin-A injection
Description: Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
Study NCT04290689 — intervention group
Intervention type: PROCEDURE
Intervention: Serial casting stretching
Description: Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
Study NCT01574612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir/hydrocortisone cream
Description: cream applied topically to lesion five times daily for five days
Study NCT04487054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pro-active palliative care
Description: Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
Study NCT01782261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: once daily subcutaneous injection
Study NCT01782261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: once daily tablet
Study NCT04061096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of cold test
Description: Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
Study NCT04061096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of cold test
Description: Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
Study NCT04061096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of electrical pulp test
Description: Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
Study NCT04061096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of electrical pulp test
Description: Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
Study NCT04061096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of pain during the treatment
Description: Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
Study NCT04061096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Evaluation of pain during the treatment
Description: Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
Study NCT01739582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Study NCT02653456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RA-308 Excimer Laser and DABRA Catheter
Description: See information already included in arm description
Study NCT02621411 — intervention group
Intervention type: DRUG
Intervention: Substance use
Description: Patients are found use of substances by preoperative screen
Study NCT01540656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)
Description: A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.
Study NCT01886092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS 3
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
Study NCT01886092 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham condition
Description: Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
Study NCT06152367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAPCells vaccine
Description: Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
Study NCT00090844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: 3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
Study NCT01835236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.
Study NCT01835236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.
Study NCT01835236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
Study NCT01835236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: First administration: Day 1 and 8 25 mg/m2 i.v. infusion~* then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion
Study NCT01835236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
Study NCT00570089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
Study NCT00570089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
Study NCT03619369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumcision
Description: Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
Study NCT03619369 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Circumcision
Description: Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
Study NCT02812550 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonoscopy procedure
Description: endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
Study NCT01675401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-loss treatment
Description: A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
Study NCT01675401 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-weight loss treatment
Description: Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
Study NCT02495064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Cream
Description: One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
Study NCT01484834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Education
Description: Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors
Study NCT01484834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise were prescribed three times a week with duration of fifteen minutes for three months.
Study NCT01484834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
Study NCT01484834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Company
Description: No intervention was applied for the participants of this group
Study NCT02256410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation
Description: The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
Study NCT00022165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: selenium
Study NCT00022165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Study NCT03076775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal glycemic control
Description: Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
Study NCT02317029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion with a pulsed biphasic waveform
Description: Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
Study NCT02317029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia during cardioversion
Description: Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
Study NCT00171223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571
Description: STI571 oral capsules or tablets.
Study NCT02317029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioversion with a biphasic truncated exponential waveform
Description: Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
Study NCT02317029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion with a biphasic truncated exponential waveform
Description: Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
Study NCT02317029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperoxia during cardioversion
Description: Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
Study NCT02317029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperoxia during cardioversion
Description: Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
Study NCT04350450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400 mg tablet
Study NCT02604212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520
Study NCT02604212 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03974711 — intervention group
Intervention type: OTHER
Intervention: In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort.
Description: There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
Study NCT02604212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study NCT02604212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study NCT02604212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Study NCT02604212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
Study NCT02604212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Study NCT00003556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-hB7.1
Study NCT00003556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: canarypox-hIL-12 melanoma vaccine
Study NCT02572869 — intervention group
Intervention type: OTHER
Intervention: physical exam
Description: Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
Study NCT02572869 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H\&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes.
Study NCT04470349 — intervention group
Intervention type: DEVICE
Intervention: LITOS
Description: Patients who received a LITOS dynamic distraction system after 31.12.2017
Study NCT04470349 — intervention group
Intervention type: DEVICE
Intervention: Ligamentotaxor
Description: Patients who received a Ligamentotaxor dynamic distraction system after 31.12.2017
Study NCT01566006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
Study NCT01566006 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
Description: effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin